Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07013643 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
75
Enrollment target
2
Study locations

NCT07013643: Recruiting Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

NCT07013643 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 75 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07013643, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
2
Study locations

Study Summary

This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.

Primary Outcome

To assess the effect of multiple doses of AZD6234, multiple doses of co-administered AZD9550 and AZD6234, and multiple doses of AZD9550 on the PK of single doses of CoC EE/LEVO.

Conditions Studied

Interventions

  • DRUG AZD6234
  • DRUG Ethinyl estradiol/Levonorgestrel (EE/LEVO)
  • DRUG Acetaminophen (APAP)
  • DRUG AZD9550

Study Locations (2)

California

  • Research Site - Glendale

Maryland

  • Research Site - Brooklyn

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-06-04
Est. Completion 2026-12-25
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT07013643 shows while recruiting

NCT07013643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% higher).

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 4 interventions - of which AZD6234 is the first listed.

NCT07013643 reports a single indexed study location in California, Maryland.

Frequently Asked Questions

What is clinical trial NCT07013643 about?

NCT07013643 is a clinical study titled "A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity". This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.

What is the current status of trial NCT07013643?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-06-04. Estimated completion is 2026-12-25.

What conditions does trial NCT07013643 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT07013643?

The interventions under investigation include: AZD6234 (DRUG), Ethinyl estradiol/Levonorgestrel (EE/LEVO) (DRUG), Acetaminophen (APAP) (DRUG), AZD9550 (DRUG).

Who is sponsoring clinical trial NCT07013643?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07013643 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07013643's enrollment target sits among peer trials

75 32nd of 119 higher than 88 of 119 other Healthy Participants trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07013643, the US trial registry maintained by the National Library of Medicine. NCT07013643 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.